Clinical Trials Logo
  1. Home
  2. Tick-Borne Encephalitis
  3. NCT00161798

Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.

Tick-borne Encephalitis Clinical Trial

Official title:
Double-blind, Randomized, Multicenter Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.

Clinical Trial Summary

The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine will be investigated in healthy children aged 6 to 16 years.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00161798
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 2
Start date September 2001
Completion date March 2002
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01031537 - Vaccine Study for Tick-Borne Encephalitis Virus (TBEV) Phase 2
Recruiting NCT02463942 - Tick-borne Encephalitis and Positive Borrelial Antibodies N/A
Completed NCT01361776 - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly Phase 2/Phase 3
Completed NCT00161863 - Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years Phase 3
Recruiting NCT05607394 - Prevalence of Tick-borne Encephalitis in the Pediatric Population Treated at the HUS and Characterization of Confirmed Pediatric Cases
Completed NCT01710189 - Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac Phase 4
Completed NCT00161772 - Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years. Phase 2
Completed NCT00161785 - Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years Phase 4
Completed NCT00118924 - Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults Phase 1
Recruiting NCT05941546 - Tick-borne Encephalitis Virus Research in Limousin
Not yet recruiting NCT04573205 - Primary TBE Vaccination for the Elderly Phase 4
Completed NCT02318069 - New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly Phase 2/Phase 3
Completed NCT04648241 - Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older Phase 3
Completed NCT00804219 - Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination Phase 4